Abstract:Chimeric antigen receptor (CAR) T cell therapy has revolutionized the management of relapsed and refractory myeloma, with excellent outcomes and a tolerable safety profile. High dose chemotherapy with autologous hematopoietic stem cell transplantation (AHCT) is established as a mainstream of newly diagnosed multiple myeloma (NDMM) management in patients who are young and fit enough to tolerate such intensity. This standard was developed based on randomized trials comparing AHCT to chemotherapy in the era prior to novel agents. More recently, larger studies have primarily shown a progression free survival (PFS) benefit of upfront AHCT, rather than overall survival (OS) benefit. There is debate about the significance of this lack of OS, acknowledging the potential confounders of the chronic nature of the disease, study design and competing harms and benefits of exposure to AHCT. Indeed upfront AHCT may not be as uniquely beneficial as we once thought, and is not without risk. New quadruple-agent regimens are highly active and effective in achieving a deep response as quantified by measurable residual disease (MRD). The high dose chemotherapy administered with AHCT imposes a burden of short and long-term adverse effects, which may alter the disease course and patient's ability to tolerate future therapies. Some high-risk subgroups may have a more valuable benefit from AHCT, though still ultimately suffer poor outcomes. When compared to the outcomes of CAR T cell therapy, the question of whether AHCT can or indeed should be deferred has become an important topic in the field. Deferring AHCT may be a personalized decision in patients who achieve MRD negativity, which is now well established as a key prognostic factor for PFS and OS. Reserving or re-administering AHCT at relapse is feasible in many cases and holds the promise of resetting the T cell compartment and opening up options for immune reengagement. It is likely that personalized MRD-guided decision making will shape how we sequence in the future, though more studies are required to delineate when this is safe and appropriate.

Management of Newly Diagnosed Multiple Myeloma Today, and in the Future

Bispecific Antibody Treatment of Multiple Myeloma: Latest Updates from the 2022 ASH Annual Meeting

Current approaches to management of newly diagnosed multiple myeloma

Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management

Progress and Paradigms in Multiple Myeloma

Novel Immunotherapies and Combinations: The Future Landscape of Multiple Myeloma Treatment

Multiple myeloma: 2020 update on diagnosis, risk‐stratification and management

Current approaches to management of high‐risk multiple myeloma

Multiple Myeloma: The Role of Autologous Stem Cell Transplantation in the Era of Immunotherapy

Antibody-Based Treatment Approaches in Multiple Myeloma

Clinical Management of the Multiple Myeloma: Reports from the 56th American Society of Hematology Annual Meeting

Recent advances in the treatment of multiple myeloma: a brief review

Monoclonal Antibodies: The Greatest Resource to Treat Multiple Myeloma

Subsequent therapy and outcomes in patients with newly diagnosed multiple myeloma experiencing disease progression after quadruplet combinations

Multiple myeloma, immunotherapy and minimal residual disease

Navigating High-Risk and Ultrahigh-Risk Multiple Myeloma: Challenges and Emerging Strategies.

The Challenging Approach to Multiple Myeloma: From Disease Diagnosis and Monitoring to Complications Management

Antibody-Drug Conjugates for Multiple Myeloma: Just the Beginning, or the Beginning of the End?

Chimeric antigen receptor T‐cells, bispecific antibodies, and antibody‐drug conjugates for multiple myeloma: An update

Autologous hematopoietic stem cell transplantation for multiple myeloma in the age of CAR T cell therapy

Multiple Myeloma: Clinical Updates From the American Society of Hematology Annual Meeting 2018